Skip to Content
  • PARP Inhibitors Do It Again

    When we last looked in on the long-running saga of PARP inhibitors around here, Tesaro had posted excellent clinical results for their compound and re-invigorat… Read More
  • Nativis Lives the Life

    I sort of hate to bring them up again, but a reader sent along this link to a story at Geekwire, all about how there’s a Seattle company has raised $10 mi… Read More
  • The Soon-Shiong Hype Machine

    I have long been suspicious of people who use the word “moonshot” in the context of biomedical research. It’s lazy shorthand for “WeR… Read More
  • Be Sure The Funds Are Deposited

    I’ve written before here about the many people who are convinced that most (or all) diseases have to do with the body’s pH – most often, you h… Read More
  • What Passes For Positive Data

    So can someone explain this one for me? Halozyme has a hyaluoronidase enzyme (PEGPH20) that they’re developing as a therapeutic agent. The idea is that it… Read More
  • More Juno CAR-T Deaths

    Remember back in the summer when Juno Therapeutics disclosed three patient deaths in one of their CAR-T oncology trials and the trial was put on hold? And then… Read More
  • More Than Was Asked For

    Via AndyBiotech on Twitter, here’s an interesting report from the New England Journal of Medicine. It describes a patient diagnosed with follicular lympho… Read More
Page 1 of 3512345...102030...Last »